Early trial tests new combo for tough brain cancer
NCT ID NCT04826393
Summary
This early-stage study tested a new combination of two immunotherapy drugs, ASP8374 and cemiplimab, in adults with an aggressive brain tumor that had returned. The main goals were to find the safest dose of the drug combo and to see if giving it right before surgery changed the immune cells in the tumor. The study was small, involving 14 people, and was the first step to see if this approach is safe and worth further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital of the University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.